Global Cell Therapy Technologies Market Introduction and Overview
According to SPER Market Research, the Global Cell Therapy Technologies Market is estimated to reach USD 11.7 billion by 2034 with a CAGR of 11.25%.
The report includes an in-depth analysis of the Global Cell Therapy Technologies Market, including market size and trends, product mix, Applications, and supplier analysis.
The global cell therapy technologies market is expected to grow from USD 4.03 billion in 2024 to USD 7.64 billion in 2030, with a CAGR of 11.25%. Growth is supported by advances in regenerative medicine, more R&D investments, and higher rates of chronic and rare diseases. Trends include using AI and machine learning to enhance production and outcomes, along with regulatory support for allogeneic therapies.
Our in-depth analysis of the Global Cell Therapy Technologies Market includes the following segments:
By Product Analysis
The product segment includes segmented media, sera & reagents, cell engineering products, cell culture vessels, cell therapy equipment, systems & software, and other products. The media, sera & reagents cell therapy technologies segment leads due to the growing use of gene therapies and cell therapies in pharmaceutical and biotech research. The cell engineering segment is expected to grow quickly because of rising investments in advanced product development. Demand for advanced cell therapy technologies and CAR-T cell therapies is also driving market growth.
By Process Analysis
Cell therapy technologies market is divided by process into cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control. The cell processing segment was the largest in 2023 due to its essential role in creating cell-based therapies. The rise in demand for personalized treatments like CAR-T and stem cell therapies boosts the need for effective cell processing solutions. Growth is also driven by more automation, GMP compliant systems, and improved protocols.
By Cell Type Analysis
The market is divided into T-cells, stem cells, and other cells by type. T cells led the market in 2023. Growth drivers include the rising incidence of diseases like cancer, more government investment in cell therapies, and demand for T-cell therapies.
By Application Analysis
The application segment includes cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications. The CVD segment is expected to grow significantly in 2023 due to the increasing prevalence of heart diseases and the demand for regenerative treatments. Advances in stem cell research, high R&D investments, and collaborations will drive innovation. Supportive regulations and production solutions enhance the potential of this segment as a key growth area for the market.
By End User Analysis
The end-user market includes biopharmaceutical and biotechnology companies, CROs and CMOs, research institutes, and cell banks. In 2023, biopharmaceutical and biotechnology companies led the segment, while CROs and CMOs are projected to grow significantly. There is a rising demand for outsourced services in cell therapy development and manufacturing. Biopharma companies increasingly rely on CROs and CMOs for expertise, cost savings, and scalability due to the growth in clinical trials and cell therapies.
By Regional Analysis
North America dominated the global cell therapy technologies market and is expected to keep its lead during the forecast period. The Asia Pacific market is predicted to grow at a significant rate due to more collaborations between local and global biotech companies, increased healthcare investment.
Market Competitive Landscape
To gain a competitive edge in the global cell therapy technologies market, companies need to focus on innovation, develop advanced technologies, and maintain a strong intellectual property portfolio. Manufacturing excellence and a strong clinical pipeline are also essential. CAR-T cell treatments are being developed and marketed by the Bristol-Myers Squibb Company. Breyanzi was approved by the European Commission (EC) in May 2023 to treat adult patients with refractory or recurrent large B-cell lymphoma.
Recent Developments:
- Lonza and Vertex Pharmaceuticals Incorporated announced a joint venture in June 2023 to enable the production of Vertex's line of experimental stem cell treatments. In particular, the VX-880 and VX-264 programs that are presently undergoing clinical trials are intended to help people with Type 1 Diabetes (T1D).
- Lonza and Vertex signed a commercial supply contract for CASGEVY, the first CRISPR/Cas9 gene-edited cell therapy, in September 2024.
- In June 2024, Thermo Fisher introduced the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators, enhancing lab automation for new cell therapy processes.
- Danaher Corporation and the University of Pennsylvania began a strategic partnership in March 2023 to address manufacturing issues that are impeding the adoption of cellular immunotherapies.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product, By Process, By Cell Type, By Application, By End User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Danaher Corporation, Merck KGaA, Thermo Fisher Scientific Inc, Lonza, Sartorius AG, Agilent Technologies, Inc, Bio-Techne, Avantor, Inc, Genscript, BD, Corning Incorporated. |
Key Topics Covered in the Report:
- Global Cell Therapy Technologies Market Size (FY’2025-FY’2034)
- Overview of Global Cell Therapy Technologies Market
- Segmentation of Global Cell Therapy Technologies Market By Product (Media, Sera & Reagents, Cell Engineering Products, Cell Culture Vessels, Cell Therapy Equipment, Systems & Software, and Other Products)
- Segmentation of Global Cell Therapy Technologies Market By Process (Cell Processing, Cell Preservation, Cell Distribution, Cell Handling, Process Monitoring & Quality Control)
- Segmentation of Global Cell Therapy Technologies Market By Cell Type (T-Cells, Stem Cells, Other Cells)
- Segmentation of Global Cell Therapy Technologies Market By Application (Cancer, Cardiovascular Disease, Orthopedic Disorders, Autoimmune Diseases, Other Applications)
- Segmentation of Global Cell Therapy Technologies Market By End User (Biopharmaceutical and Biotechnology Companies, CROs and CMOs, Research Institutes, Cell Banks)
- Statistical Snap of Global Cell Therapy Technologies Market
- Expansion Analysis of Global Cell Therapy Technologies Market
- Problems and Obstacles in Global Cell Therapy Technologies Market
- Competitive Landscape in the Global Cell Therapy Technologies Market
- Details on Current Investment in Global Cell Therapy Technologies Market
- Competitive Analysis of Global Cell Therapy Technologies Market
- Prominent Players in the Global Cell Therapy Technologies Market
- SWOT Analysis of Global Cell Therapy Technologies Market
- Global Cell Therapy Technologies Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Cell Therapy Technologies Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cell Therapy Technologies Market
7. Global Cell Therapy Technologies Market, By Product (USD Million) 2025-2034
7.1. Media
7.2. Sera & Reagents,
7.3. Cell Engineering Products
7.4. Cell Culture Vessels
7.5. Cell Therapy Equipment
7.6. Systems & Software
7.7. Other Products
8. Global Cell Therapy Technologies Market, By Process (USD Million) 2025-2034
8.1. Cell Processing
8.2. Cell Preservation
8.3. Cell Distribution
8.4. Cell Handling
8.5. Process Monitoring & Quality Control
9. Global Cell Therapy Technologies Market, By Cell type (USD Million) 2025-2034
9.1. T-Cells
9.2. Stem cells
10. Global Cell Therapy Technologies Market, By Application (USD Million) 2025-2034
10.1. Cancer
10.2. Cardiovascular disease (CVD)
10.3. Orthopaedic disorders
10.4. Autoimmune diseases
10.5. Other applications
11. Global Cell Therapy Technologies Market, By End User (USD Million) 2025-2034
11.1. Biopharmaceutical & Biotechnology Companies
11.2. CROs & CMOs
11.3. Research Institutes
11.4. Cell Banks
12. Global Cell Therapy Technologies Market Forecast, 2025-2034 (USD Million)
12.1. Global Cell Therapy Technologies Market Size and Market Share
13. Global Cell Therapy Technologies Market, By Region, 2025-2034 (USD Million)
13.1. Asia-Pacific
13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada
13.4.2. Mexico
13.4.3. United States
13.5. Latin America
13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America
14. Company Profile
14.1. Danaher Corporation
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Merck KGaA
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Thermo Fisher Scientific Inc
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. Lonza
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Sartorius AG
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Agilent Technologies, Inc
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Bio-Techne
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Avantor, Inc
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Genscript
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. BD
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Corning Incorporated
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links